Gain Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $53.60M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | After market close | – | $-0.11 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 11, 2026 | After market close | – | $-0.13 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 26, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | After market close | – | $-0.15 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 27, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | After market close | – | $-0.17 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | After market close | – | $-0.42 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | After market close | – | $-0.22 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 26, 2024 | After market close | – | – | – |
Press releases
Announcements Gain Therapeutics filed with the SEC
Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Gain Therapeutics Presents Additional Clinical
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Certain statements set forth in this presentation are forward-looking and reflect the Company’s plans, beliefs, expectations and current views with respect to, among other things, future events and financial performance (collectively referred to herein as
Regulation FD disclosure · EX-99.1 to Form 8-K
Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Gain Therapeutics Announces Proposed Public
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Pricing of $7.0 Million Public Offering
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Gain Therapeutics Presents Additional Preclinical
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Corporate Presentation September 2024 GAIN THERAPEUTICS Corporate Presentation April 2025 NASDAQ: GANX
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Gain Therapeutics CEO Gene Mack Issues Letter
Regulation FD disclosure · EX-99.1 to Form 8-K
Appoints Gene Mack as Chief Executive Officer and Director
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Gain Therapeutics Presents Preclinical GT-02287
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Gain Therapeutics Announces the Completion
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Appoints Gene Mack as Interim CEO
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
13, 2024 – Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced that
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Pricing of $11.0 Million Public Offering
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Gain Therapeutics Bolsters Management Team
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
GAIN THERAPEUTICS’ CEO MATTHIAS ALDER ISSUES LETTER TO SHAREHOLDERS
Regulation FD disclosure · EX-99.1 to Form 8-K
2023 – Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced that
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Pricing of $9.4 Million Public Offering and
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
GAIN THERAPEUTICS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND BUSINESS UPDATE
Results of operations · EX-99.1 to Form 8-K
Gain Therapeutics Appoints C. Evan Ballantyne
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
GAIN THERAPEUTICS REPORTS FULL YEAR 2022 FINANCIAL RESULTS AND BUSINESS UPDATE
Results of operations · EX-99.1 to Form 8-K
GAIN THERAPEUTICS, INC. REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND BUSINESS UPDATE
Results of operations · EX-99.1 to Form 8-K
THERAPEUTICS Announces PROMOTION OF Matthias Alder TO chief executive officer
Executive or director change · Other events · EX-99.1 to Form 8-K
GAIN THERAPEUTICS, INC. REPORTS second QUARTER 2022 FINANCIAL RESULTS AND BUSINESS UPDATE
Results of operations · EX-99.1 to Form 8-K
GAIN THERAPEUTICS, INC. REPORTS First QUARTER 2022 FINANCIAL RESULTS AND BUSINESS UPDATE
Results of operations · EX-99.1 to Form 8-K
Gain Therapeutics, Inc. Reports Full Year 2021
Results of operations · EX-99.1 to Form 8-K